Statins are among the most extensively studied medications in history. Since the approval of lovastatin in 1987, this class of drugs has fundamentally changed the management of cardiovascular disease by providing a reliable, effective means of lowering LDL ('bad') cholesterol.

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. When the liver produces less cholesterol, it upregulates LDL receptors on its surface, pulling more LDL cholesterol out of the bloodstream. The net effect is a 30–55% reduction in LDL cholesterol, depending on the specific statin and dose. Additionally, statins have pleiotropic effects including anti-inflammatory properties, plaque stabilization, and improved endothelial function.

Not all statins are created equal. High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce LDL by ≥50%. Moderate-intensity options (atorvastatin 10–20 mg, simvastatin 20–40 mg, pravastatin 40 mg) reduce LDL by 30–49%. Current guidelines recommend high-intensity statin therapy for patients with established cardiovascular disease or very high risk, and moderate-intensity for primary prevention in appropriate candidates.

Myalgia (muscle pain or weakness without CK elevation) affects 5–10% of statin users in clinical practice. True statin-induced myopathy (with elevated CK) is rare (<0.1%), and rhabdomyolysis is extremely rare (<0.01%). Notably, the nocebo effect plays a significant role — in blinded trials, muscle symptoms occur at similar rates in statin and placebo groups. If muscle symptoms develop, switching to a different statin, using alternate-day dosing, or trying rosuvastatin (which has less muscle penetration) often resolves the issue.

Statins slightly increase the risk of developing type 2 diabetes (about 1 additional case per 255 patients treated for 4 years), but the cardiovascular benefits far outweigh this risk. Liver enzyme elevations are uncommon and rarely clinically significant. Statins should not be used during pregnancy.

For patients who cannot achieve target LDL levels with statins alone, ezetimibe can be added to block intestinal cholesterol absorption, providing an additional 15–20% LDL reduction. PCSK9 inhibitors (evolocumab, alirocumab) are injectable biologics that can reduce LDL by 50–60% on top of statin therapy, reserved for very high-risk patients.

Report unexplained muscle pain, dark urine, or unusual fatigue to your doctor. Never stop statin therapy on your own — sudden discontinuation can increase cardiovascular risk. Discuss any concerns about side effects with your healthcare provider; there are usually alternative options available.